c19early.org COVID-19 treatment researchCOVID-19 treatments

A National, Multi-Center, Open-Label, Three-Arm, Phase II Study to Investigate the Effect of Montelukast Between Emergency Room Visits and Hospitalizations in COVID-19 Pneumonia in Comparison With Standard Treatment

Durdagi et al., NCT04718285, NCT04718285, Jun 2022

Montelukast for COVID-19

32nd treatment shown to reduce risk in November 2021, now with p = 0.0041 from 9 studies.
Lower risk for hospitalization and cases.

No treatment is 100% effective.
Protocols combine treatments.

6,700+ studies · 220+ treatments

c19early.org
Meta-analysis
Estimated 380 patient montelukast early treatment RCT with results not reported over 4 years after estimated completion.
2 montelukast RCTs have results missing long after expected1,2
The trials report an estimated total of 664 patients.
Important missing comments or errors? Let us know.
Durdagi et al., 1 Jun 2022, Randomized Controlled Trial, Turkey, trial NCT04718285 (history). Contact: serdar.durdagi@med.bau.edu.tr.